The mitochondrial targeting drug of gallium-based organic frameworks produces ROS and releases L-Arg, which reacts with ROS to generate NO, downregulates HIF-1α expression to improve tumor hypoxia, and enhances immune responses by increasing calreticulin (CRT), high-mobility group box 1 (HMGB1), and T cell proliferation (214). Here, HMGB1 is linked to neoplasm.